N/A N=153 Treatment for Adolescent Marijuana Abuse
Marijuana Abuse
Primary: Marijuana Abstinence (2 Weeks or Greater) — 72.5; 68.6; 45.1 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=145 Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women
Neoplasms, Ovarian
Primary: Progression-free Survival (PFS) — 18.1; 18.1 months
Phase 2 N=49 Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
Exudative Age-Related Macular Degeneration
Primary: Mean Reduction From Baseline in Central Subfield (CSF) Retinal Thickness at Week 4 — 514.2; 551.8; -12.1; 199.9 microns
Phase 2 N=61 Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Percentage of Participants With Objective Response: Phase 2 — 28.6; 48.8; 39.0 Percentage of participants — p=0.9726
N/A N=86 Reintegration: The Role of Spouse Telephone BATTLEMIND Pilot Study
Military Spouses · Support Groups · Stress Disorders
Primary: Spouse Self-report of Depression — 8.9; 7.4; 6.9 units on a scale — p=.003
Phase 2 N=10 Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide
Pulmonary Arterial Hypertension
Primary: Incidence and Severity of Treatment Emergent Adverse Events; Unanticipated Adverse Device Effects and Changes From Baseline to End-of-study in Clinical Lab Parameters…
Phase 2 N=70 AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery
Left Atrial Appendage Exclusion
Primary: Rate of Device Related Serious Adverse Events — 0 Number of participants
Phase 2 N=103 Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1
Depression · Marijuana Abuse
Primary: Two Consecutive Weeks of Marijuana Abstinence — 19; 6 participants — p=<0.01
Phase 3 N=791 Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Renal Cell Carcinoma
Primary: Progression-Free Survival (PFS): Independent-Assessment — 9.1; 9.3 months — p=0.8
Phase 3 N=1,450 CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride
Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline to Week 52 — -0.82; -0.93; -0.81 Percent
Phase 3 N=72 Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression
Affective Disorders
Primary: 21 Item Hamilton Depression Rating Scale — 13.6; 11.0 Units on Hamilton Depression Scale
Phase 2 N=7 TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
Influenza
Primary: Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption — 1; 1; 1 number of participants with AEs
Phase 2 N=49 A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection
Hepatitis C, Chronic
Primary: Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Day 15 — 6.61; 6.21; 6.15; 6.65 log10 IU/ml
Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Phase 3 N=60 Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics
Rhinitis
Primary: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs) — 15; 17; 32; 0 participants